Mary Ann Fletcher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mary Ann Fletcher has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Dolores Perdomo
Department of Psychology, University of Miami, USA
2 shared publications - Michael H. Antoni
Department of Psychology, University of Miami
2 shared publications - Nancy Klimas
Institute for Neuro-Immune Medicine, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL 33328, USA
2 shared publications - Sara J. Czaja
Weill Cornell Medicine
2 shared publications - AnneLiese Smylie
Department of Medicine, University of Alberta, Edmonton, AB, Canada
1 shared publication - Ben Z. Katz
Department of Pediatrics, Northwestern University Feinberg School of Medicine, Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, USA
1 shared publication
Latest Publications
- 1 February 2020
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 129, 109893
Post-exertional malaise is associated with greater symptom burden and psychological distress in patients diagnosed with Chronic Fatigue Syndrome
- 1 February 2020
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 129, 109893
Post-exertional malaise is associated with greater symptom burden and psychological distress in patients diagnosed with Chronic Fatigue Syndrome
- Open Access
- 10 March 2016
- Published by Springer Nature in BMC Immunology
- Vol. 17 (1) , 1-11
Illness progression in chronic fatigue syndrome: a shifting immune baseline
Validation of biomarkers for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) across data sets has proven disappointing. As immune signature may be affected by many factors, our objective was to explore the shift in discriminatory cytokines across ME/CFS subjects separated by duration of illness. Cytokine expression collected at rest across multiple studies for female ME/CFS subjects (i) 18 years or younger, ill for 2 years or less (n = 18), (ii) 18–50 years of age, ill for 7 years (n = 22), and (iii) age 50 years or older (n = 28), ill for 11 years on average. Control subjects were matched for age and body mass index (BMI). Data describing the levels of 16 cytokines using a chemiluminescent assay was used to support the identification of separate linear classification models for each subgroup. In order to isolate the effects of duration of illness alone, cytokines that changed significantly with age in the healthy control subjects were excluded a priori. Optimal selection of cytokines in each group resulted in subsets of IL-1α, 6, 8, 15 and TNFα. Common to any 2 of 3 groups were IL-1α, 6 and 8. Setting these 3 markers as a triple screen and adjusting their contribution according to illness duration sub-groups produced ME/CFS classification accuracies of 75–88 %. The contribution of IL-1α, higher in recently ill adolescent ME/CFS subjects was progressively less important with duration. While high levels of IL-8 screened positive for ME/CFS in the recently afflicted, the opposite was true for subjects ill for more than 2 years. Similarly, while low levels of IL-6 suggested early ME/CFS, the reverse was true in subjects over 18 years of age ill for more than 2 years. These preliminary results suggest that IL-1α, 6 and 8 adjusted for illness duration may serve as robust biomarkers, independent of age, in screening for ME/CFS.
- 10 March 2016
- Published by Springer Nature in BMC Immunology
- Vol. 17 (1) , 1-11
Open AccessIllness progression in chronic fatigue syndrome: a shifting immune baseline
Validation of biomarkers for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) across data sets has proven disappointing. As immune signature may be affected by many factors, our objective was to explore the shift in discriminatory cytokines across ME/CFS subjects separated by duration of illness. Cytokine expression collected at rest across multiple studies for female ME/CFS subjects (i) 18 years or younger, ill for 2 years or less (n = 18), (ii) 18–50 years of age, ill for 7 years (n = 22), and (iii) age 50 years or older (n = 28), ill for 11 years on average. Control subjects were matched for age and body mass index (BMI). Data describing the levels of 16 cytokines using a chemiluminescent assay was used to support the identification of separate linear classification models for each subgroup. In order to isolate the effects of duration of illness alone, cytokines that changed significantly with age in the healthy control subjects were excluded a priori. Optimal selection of cytokines in each group resulted in subsets of IL-1α, 6, 8, 15 and TNFα. Common to any 2 of 3 groups were IL-1α, 6 and 8. Setting these 3 markers as a triple screen and adjusting their contribution according to illness duration sub-groups produced ME/CFS classification accuracies of 75–88 %. The contribution of IL-1α, higher in recently ill adolescent ME/CFS subjects was progressively less important with duration. While high levels of IL-8 screened positive for ME/CFS in the recently afflicted, the opposite was true for subjects ill for more than 2 years. Similarly, while low levels of IL-6 suggested early ME/CFS, the reverse was true in subjects over 18 years of age ill for more than 2 years. These preliminary results suggest that IL-1α, 6 and 8 adjusted for illness duration may serve as robust biomarkers, independent of age, in screening for ME/CFS.
- 8 May 2015
- Published by Taylor & Francis in Fatigue: Biomedicine, Health & Behavior
- Vol. 3 (3) , 142-155
Perceived fatigue interference and depressed mood: comparison of chronic fatigue syndrome/myalgic encephalomyelitis patients with fatigued breast cancer survivors
Objective: Persistent fatigue and depressive symptoms are both highly prevalent among patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) as well as breast cancer survivors. This study aimed to assess and directly compare perceptions of fatigue as highly interfering in one's daily functioning in both patient populations to better understand their relationships with depressed mood. Methods: Participants were 95 female CFS/ME patients and 67 females who were approximately five years post-treatment for stage 0–III breast cancer presenting with clinically elevated fatigue severity. Self-report measures were obtained on participants' fatigue-related interference in daily functioning and fatigue severity as well as depressed mood. Hierarchical regression was used to test effects controlling for relevant demographic, psychosocial, and medical covariates. Results: CFS/ME patients endorsed greater depressed mood and fatigue interference than did fatigued breast cancer survivors, p < .001. These factors were significantly positively correlated among CFS/ME patients (β = .36, p < .001), but not among the fatigued breast cancer survivors (β = .18, p = .19). Conclusions: CFS/ME patients reported elevated fatigue symptoms and depression relative to fatigued breast cancer survivors. In the former group, greater depressed mood was highly and significantly associated with greater fatigue-related inference in daily activities. Potential targets for cognitive behavioral interventions are discussed.
- 8 May 2015
- Published by Taylor & Francis in Fatigue: Biomedicine, Health & Behavior
- Vol. 3 (3) , 142-155
Perceived fatigue interference and depressed mood: comparison of chronic fatigue syndrome/myalgic encephalomyelitis patients with fatigued breast cancer survivors
Objective: Persistent fatigue and depressive symptoms are both highly prevalent among patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) as well as breast cancer survivors. This study aimed to assess and directly compare perceptions of fatigue as highly interfering in one's daily functioning in both patient populations to better understand their relationships with depressed mood. Methods: Participants were 95 female CFS/ME patients and 67 females who were approximately five years post-treatment for stage 0–III breast cancer presenting with clinically elevated fatigue severity. Self-report measures were obtained on participants' fatigue-related interference in daily functioning and fatigue severity as well as depressed mood. Hierarchical regression was used to test effects controlling for relevant demographic, psychosocial, and medical covariates. Results: CFS/ME patients endorsed greater depressed mood and fatigue interference than did fatigued breast cancer survivors, p < .001. These factors were significantly positively correlated among CFS/ME patients (β = .36, p < .001), but not among the fatigued breast cancer survivors (β = .18, p = .19). Conclusions: CFS/ME patients reported elevated fatigue symptoms and depression relative to fatigued breast cancer survivors. In the former group, greater depressed mood was highly and significantly associated with greater fatigue-related inference in daily activities. Potential targets for cognitive behavioral interventions are discussed.